As part of an ongoing effort to develop new antiviral nucleoside analogs, our interest was drawn to N(1)-aryl purines as a novel structural class and potential scaffold for drug discovery. Herein, we describe the synthesis of N(1)-3-fluorophenyl-inosine (FPI) and N(1)-3-fluorophenyl-hypoxanthine (FP-Hx) and their antiviral activity against hantaviruses. The EC(50) for FPI and FP-Hx were 94 and 234microM, respectively, against Hantaan virus. FPI was not toxic to mammalian cells at concentrations that exhibited antiviral activity. Analysis of its metabolism revealed a low conversion of FPI in Vero E6 or human cells to a 5'-triphosphate, and it was a poor substrate for human purine nucleoside phosphorylase. Further, the compound did not alter GTP levels indicating FPI does not inhibit inosine monophosphate dehydrogenase. With respect to the virus, FPI did not decrease viral RNA levels or increase the mutation frequency of the viral RNA. This suggests that the antiviral activity of FPI might be solely due to the interaction of FPI or its metabolites with viral or host proteins involved in post-replication events that would affect the levels of infectious virus released. Synthesis of other compounds structurally similar to FPI is warranted to identify more potent agents that selectively abrogate production of infectious virus.
As part of an ongoing effort to develop new antiviral nucleoside analogs, our interest was drawn to n class="Chemical">N(1)-aryl purines as a novel structural class and potential scaffold for drug discovery. Herein, we describe the synthesis of N(1)-3-fluorophenyl-inosine (FPI) and N(1)-3-fluorophenyl-hypoxanthine (FP-Hx) and their antiviral activity against hantaviruses. The EC(50) for FPI and FP-Hx were 94 and 234microM, respectively, against Hantaan virus. FPI was not toxic to mammalian cells at concentrations that exhibited antiviral activity. Analysis of its metabolism revealed a low conversion of FPI in Vero E6 or human cells to a 5'-triphosphate, and it was a poor substrate for humanpurine nucleoside phosphorylase. Further, the compound did not alter GTP levels indicating FPI does not inhibit inosine monophosphate dehydrogenase. With respect to the virus, FPI did not decrease viral RNA levels or increase the mutation frequency of the viral RNA. This suggests that the antiviral activity of FPI might be solely due to the interaction of FPI or its metabolites with viral or host proteins involved in post-replication events that would affect the levels of infectious virus released. Synthesis of other compounds structurally similar to FPI is warranted to identify more potent agents that selectively abrogate production of infectious virus.
Authors: R Yanagihara; C T Chin; M B Weiss; D C Gajdusek; A R Diwan; J B Poland; K T Kleeman; C M Wilfert; G Meiklejohn; W P Glezen Journal: Am J Trop Med Hyg Date: 1985-03 Impact factor: 2.345
Authors: Gregory J Mertz; Lil Miedzinski; Diane Goade; Andrew T Pavia; Brian Hjelle; Christine O Hansbarger; Howard Levy; Frederick T Koster; Kenneth Baum; Adeline Lindemulder; Wenquan Wang; Laura Riser; Humberto Fernandez; Richard J Whitley Journal: Clin Infect Dis Date: 2004-10-11 Impact factor: 9.079
Authors: Dong-Hoon Chung; Sidath C Kumarapperuma; Yanjie Sun; Qianjun Li; Yong-Kyu Chu; Jeffrey B Arterburn; William B Parker; Jeffrey Smith; Kristin Spik; Harish N Ramanathan; Connie S Schmaljohn; Colleen B Jonsson Journal: Antiviral Res Date: 2008-03-17 Impact factor: 5.970
Authors: Jason Botten; Katy Mirowsky; Donna Kusewitt; Chunyan Ye; Keith Gottlieb; Joseph Prescott; Brian Hjelle Journal: J Virol Date: 2003-01 Impact factor: 5.103
Authors: L E Chapman; G J Mertz; C J Peters; H M Jolson; A S Khan; T G Ksiazek; F T Koster; K F Baum; P E Rollin; A T Pavia; R C Holman; J C Christenson; P J Rubin; R E Behrman; L J Bell; G L Simpson; R F Sadek Journal: Antivir Ther Date: 1999